Skip to Main Content

Under pressure to widen global access to Covid-19 vaccines, the Biden administration plans to invest billions of dollars to expand U.S. manufacturing capacity with an eye toward producing at least 1 billion doses annually no later than the second half of 2022.

But the effort was greeted with mixed reactions. Patient advocates lauded the move, but at the same time, they lamented such a step was not taken months ago and questioned some of the details.


“Late is definitely better than never,” said Jayasree Iyer, who heads the Access to Medicines Foundation, which tracks moves by governments and companies to provide medication to low-income countries. “But so much more may have been accomplished if such steps were taken sooner.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.